<DOC>
	<DOC>NCT02726009</DOC>
	<brief_summary>The purpose of this open-label, single-arm, multicenter, post-marketing trial is to evaluate long-term safety of Firmagon® in approximately 230 Indian patients diagnosed with advanced hormone-dependent prostate cancer requiring androgen deprivation therapy.</brief_summary>
	<brief_title>A Trial to Evaluate Safety of Firmagon® (Degarelix) in Indian Patients Diagnosed With Advanced Hormone-dependent Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>Has given written informed consent before any studyrelated activity is performed Advanced hormonedependent prostate cancer for which androgen deprivation therapy is indicated Age greater than or equal to 18 years and less than 80 years Advanced hormonedependent prostate cancer without any other clinically significant disorder PSA ≥ 2 ng/mL at screening Previous or concurrent hormonal management of prostate cancer Contraindication for prescription of Firmagon® Concurrent treatment with a 5αreductase inhibitor Considered as a candidate for curative therapy History of severe untreated asthma, anaphylactic reactions or severe urticaria and/or angioedema QTc interval over 450 msec or risk factors for torsades de pointes or on Class IA and Class III anti arrhythmic medications Cancer within the last 5 years except prostate cancer and surgically removed basal or squamous cell carcinoma of the skin Known or suspected hepatic, symptomatic biliary disease (this includes moderate to severe chronic hepatic impairment) Patients with urinary catheterization / clinically significant laboratory abnormalities / disorders other than prostate cancer Patient with Hepatitis B Virus (HBV), Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) infections</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>